North America is “Ground Zero” For Babesiosis
https://www.lymedisease.org/ground-zero-babesiosis/
https://www.lymedisease.org/ground-zero-babesiosis/
https://rawlsmd.com/health-articles/real-talk-new-johns-hopkins-study-5-herbs-that-can-kill-babesia
For more:
https://www.lymedisease.org/chronic-lyme-gut-study-reopens/
April 29, 2021
Last month, we sent out a special announcement about researchers working to develop a diagnostic test for chronic Lyme disease.
They were seeking participants in a study of how chronic Lyme disease affects the gut’s microbiome.
Response from the Lyme community was overwhelming. Within 12 hours, every slot in the study was filled! We had to tell people that enrollment was closed and shut down our application link.
However, because of that enthusiastic response, Flightpath Biosciences, the company conducting the study, applied for regulatory approval to expand the number of participants.
They obtained that approval and have reopened applications for their “Study of a Potential Test for Persistent Lyme Disease.”
Here’s a recap of information we originally posted last month:
Recent research by Professor Kim Lewis, of Boston’s Northeastern University, has shown that changes in the bacteria in a person’s gastrointestinal tract may be predictive of late-stage Lyme disease.
In general, bacteria in the gut are a good indicator of our overall health. These bacteria strongly influence our immune system, and in some cases, our microbiomes may be as important as our genetics in predicting diseases.
In consultation with Professor Lewis and building on his work, Flightpath Biosciences plans to study blood and stool samples from chronic Lyme patients and compare them to those of healthy people.
They’ll be looking for biomarkers—objective signs that are distinctive to chronic Lyme disease. If found, these biomarkers could lead to a new way of diagnosing the disease and demonstrating its active presence in patients.
One of the biggest barriers for chronic Lyme disease patients has been the lack of a test that can detect on-going disease. The company’s new study and related research could hold the key to finally developing an accurate test and potentially new treatments.
That’s where you come in. If you are willing to take part in this research, the requirements for participating in the study criteria are below.
To be eligible, you must be:
Participants:
Those who complete the study will receive a $50 Amazon gift card.
When you apply to take part, you’ll be asked to fill out a survey with questions about your health history, including what medications you are taking or have taken in the past.
If you meet the criteria, a stool sample kit will be sent to you, with instructions on how to collect and submit it.
Then, a phlebotomist will schedule a visit with you to draw your blood sample. At that point, you are done with the process, and you’ll be sent your Amazon card.
LymeDisease.org is providing this information from Flightpath Biosciences as part of our mission to accelerate research in Lyme disease. One question the company hopes to answer is whether there are differences between the microbiomes or blood samples of males and females in this population. So, while this study is re-opening to all genders, if you know of a male with persistent Lyme disease, please encourage them to enroll.
https://pubmed.ncbi.nlm.nih.gov/33789412/
PMID: 33789412
Free article
https://www.belmontlawreview.org/articles/volume-8-issue-1-2020/

VOLUME 8, ISSUE 1: 2020
Creighton R. Meland, Jr.
For the excellently written paper for the Belmont Law Review, on the state of affairs with Lyme disease, please see this pdf: https://cpb-us-w2.wpmucdn.com/blogs.belmont.edu/dist/8/25/files/2020/11/Meland_95-163.pdf
Table of Contents:
INTRODUCTION 96
I. WHAT IS LYME DISEASE AND WHY IS IT MEDICALLY CONTROVERSIAL? 97
A. What is Lyme Disease? 97
B. Lyme Disease Detection and Diagnosis 101
C. Lyme Disease Treatment Regimens 104
1. IDSA v. ILADS 104
2. Coinfections and their Effect on Treatment 106
D. Lyme Disease is not a Research Priority 107
II. LYME DISEASE LEGAL ISSUES 108
A. IDSA and CDC Set Treatment Standards 108
1. Effects on Quality and Availability of Care 108
2. Antitrust Implications 112
B. State Lyme Disease Legislation 122
1. Health Insurance Coverage Mandates 122
2. Professional Standards 125
3. Lyme Testing Disclosures 127
4. Safe Harbors 130
5. Awareness, Prevention, and Government Support 133
**J.D. University of Michigan; B.S. Economics, Major in Finance, Wharton School, Undergraduate Division, University of Pennsylvania.**
I am grateful to Belmont Law Review for the opportunity to critique laws designed to redress health care problems presented by Lyme disease. Despite a pervasive presence and severe symptoms, Lyme disease is widely misunderstood by the medical community and too often goes untreated or improperly treated. While we await advances in medical science, the law can help those who suffer. I recognize and thank the International Lyme and Associated Diseases Society and its many contributors, who have deepened my understanding of medical problems associated with Lyme disease. These insights have influenced positively the form of the work I now submit.